| Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer E Van Cutsem, H Van De Velde, P Karasek, H Oettle, WL Vervenne, ... Journal of clinical oncology 22 (8), 1430-1438, 2004 | 965 | 2004 |
| Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer S Rao, D Cunningham, A De Gramont, W Scheithauer, M Smakal, ... Journal of Clinical Oncology 22 (19), 3950-3957, 2004 | 280 | 2004 |
| Model evaluation of continuous data pharmacometric models: metrics and graphics THT Nguyen, MS Mouksassi, N Holford, N Al‐Huniti, I Freedman, ... CPT: pharmacometrics & systems pharmacology 6 (2), 87-109, 2017 | 269 | 2017 |
| Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma SJ Cohen, L Ho, S Ranganathan, JL Abbruzzese, RK Alpaugh, M Beard, ... Journal of Clinical Oncology 21 (7), 1301-1306, 2003 | 213 | 2003 |
| Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer SRD Johnston, T Hickish, P Ellis, S Houston, L Kelland, M Dowsett, ... Journal of clinical oncology 21 (13), 2492-2499, 2003 | 212 | 2003 |
| Multi-dimensional function approximation and regression estimation F Pérez-Cruz, G Camps-Valls, E Soria-Olivas, JJ Pérez-Ruixo, ... International conference on artificial neural networks, 757-762, 2002 | 143 | 2002 |
| Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis L Sutjandra, RD Rodriguez, S Doshi, M Ma, MC Peterson, GR Jang, ... Clinical pharmacokinetics 50, 793-807, 2011 | 98 | 2011 |
| Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys JJ Xiao, W Krzyzanski, YM Wang, H Li, MJ Rose, M Ma, Y Wu, B Hinkle, ... The AAPS journal 12, 646-657, 2010 | 95 | 2010 |
| Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours L Gibiansky, L Sutjandra, S Doshi, J Zheng, W Sohn, MC Peterson, ... Clinical pharmacokinetics 51, 247-260, 2012 | 75 | 2012 |
| Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects YMC Wang, W Krzyzanski, S Doshi, JJ Xiao, JJ Pérez-Ruixo, AT Chow The AAPS journal 12, 729-740, 2010 | 74 | 2010 |
| Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab BB Yang, P Lum, A Chen, R Arends, L Roskos, B Smith, JJP Ruixo Clinical pharmacokinetics 49, 729-740, 2010 | 74 | 2010 |
| Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma XS Xu, X Yan, T Puchalski, S Lonial, HM Lokhorst, PM Voorhees, ... Clinical Pharmacology & Therapeutics 101 (6), 721-724, 2017 | 73* | 2017 |
| A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy SRD Johnston, VF Semiglazov, GM Manikhas, D Spaeth, G Romieu, ... Breast cancer research and treatment 110, 327-335, 2008 | 70 | 2008 |
| Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response–Based Meta-Analysis JW Mandema, J Zheng, C Libanati, JJ Perez Ruixo The Journal of Clinical Endocrinology & Metabolism 99 (10), 3746-3755, 2014 | 68 | 2014 |
| Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients M Zhu, S Doshi, PO Gisleskog, KS Oliner, JJ Perez Ruixo, E Loh, Y Zhang Journal of pharmaceutical sciences 103 (1), 328-336, 2014 | 66 | 2014 |
| Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects P Olsson-Gisleskog, P Jacqmin, JJ Perez-Ruixo Clinical pharmacokinetics 46, 159-173, 2007 | 63 | 2007 |
| Prediction of cyclosporine dosage in patients after kidney transplantation using neural networks G Camps-Valls, B Porta-Oltra, E Soria-Olivas, JD Martín-Guerrero, ... IEEE Transactions on Biomedical Engineering 50 (4), 442-448, 2003 | 62 | 2003 |
| A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma JE Rosenberg, H von der Maase, JD Seigne, J Mardiak, DJ Vaughn, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 61 | 2005 |
| Population pharmacokinetic meta-analysis of trabectedin (ET-743, yondelis®) in cancer patients JJ Perez-Ruixo, P Zannikos, S Hirankam, K Stuyckens, EA Ludwig, ... Clinical pharmacokinetics 46, 867-884, 2007 | 57 | 2007 |
| Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin K Jolling, JJP Ruixo, A Hemeryck, A Vermeulen, T Greway European journal of pharmaceutical sciences 24 (5), 465-475, 2005 | 56 | 2005 |
Sameer DoshiAmgen Inc.Verified email at amgen.com
